Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abbvie Inc (ABBV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 118,640,928
  • Shares Outstanding, K 1,475,083
  • Annual Sales, $ 32,753 M
  • Annual Income, $ 5,687 M
  • 60-Month Beta 1.17
  • Price/Sales 3.64
  • Price/Cash Flow 8.65
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate 2.05
  • Number of Estimates 5
  • High Estimate 2.07
  • Low Estimate 2.02
  • Prior Year 1.87
  • Growth Rate Est. (year over year) +9.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
77.09 +3.94%
on 03/08/19
81.75 -1.98%
on 03/18/19
+1.38 (+1.75%)
since 02/21/19
3-Month
75.77 +5.75%
on 01/29/19
92.99 -13.83%
on 12/31/18
-4.79 (-5.64%)
since 12/21/18
52-Week
75.77 +5.75%
on 01/29/19
107.25 -25.29%
on 05/21/18
-32.32 (-28.74%)
since 03/21/18

Most Recent Stories

More News
AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.

JNJ : 138.62 (+0.97%)
ABBV : 80.55 (+0.15%)
TEVA : 17.06 (+1.19%)
RHHBY : 33.9900 (-0.29%)
BioMed Realty Launches The Second Phase At Gateway of Pacific - Expanding Its Landmark Campus At The Front Door Of San Francisco's Premier Life Science Market

BioMed Realty, a Blackstone portfolio company and a leading provider of real estate solutions for the life science industry, announced today that it has commenced construction on Phase II of the multi-phase,...

ABBV : 80.55 (+0.15%)
Labaton Sucharow Files Class Action against AbbVie And Other Drugmakers, Alleging Anti-Competitive Practices to Block Competition for Blockbuster Drug Humira in the United States

Labaton Sucharow LLP has filed a class action lawsuit against drugmaker AbbVie Inc. and a group of global rivals, alleging the company colluded to divide the market for AbbVie's blockbuster drug Humira...

ABBV : 80.55 (+0.15%)
AbbVie Provides Update on VENCLEXTA®/VENCLYXTO® (venetoclax) Multiple Myeloma Program

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.S. Food and Drug Administration (FDA) has placed a partial clinical hold on all clinical trials evaluating...

ABBV : 80.55 (+0.15%)
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

AbbVie (ABBV) closed at $80.65 in the latest trading session, marking a -0.85% move from the prior day.

ABBV : 80.55 (+0.15%)
BioMed Realty Expands Life Science Footprint In San Francisco Bay Area With Campus Acquisition Of The Emeryville Center for Innovation

BioMed Realty, a Blackstone portfolio company, announced today the acquisition of the Emeryville Center for Innovation, located in Emeryville, California, for approximately $135 million. This latest investment...

NVS : 93.63 (+0.16%)
ABBV : 80.55 (+0.15%)
Look for Shares of Abbvie Inc to Potentially Pullback after Yesterday's 1.43% Rise

Abbvie Inc (NYSE:ABBV) traded in a range yesterday that spanned from a low of $78.86 to a high of $80.06. Yesterday, the shares gained 1.4%, which took the trading range above the 3-day high of $79.19...

ABBV : 80.55 (+0.15%)
Roche Receives EC Approval for Label Expansion of Hemlibra

Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.

NVS : 93.63 (+0.16%)
ABBV : 80.55 (+0.15%)
RHHBY : 33.9900 (-0.29%)
AMGN : 191.82 (+0.37%)
Theravance (TBPH) Starts Dosing in Ulcerative Colitis Study

Theravance (TBPH) commences phase IIb/III study for its gut-selective pan- JAK inhibitor, TD-1473 in patients with moderately to severely active ulcerative colitis.

TBPH : 24.96 (+3.14%)
JNJ : 138.62 (+0.97%)
ABBV : 80.55 (+0.15%)
PFE : 42.56 (+0.92%)
Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval

FDA approves Pfizer's (PFE) biosimilar version Roche's (RHHBY) breast cancer drug, Herceptin.

ABBV : 80.55 (+0.15%)
RHHBY : 33.9900 (-0.29%)
AMGN : 191.82 (+0.37%)
PFE : 42.56 (+0.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade ABBV with:

Business Summary

AbbVie is a global, research-based biopharmaceutical company. AbbVie combines the focus and passion of a leading-edge biotech with the expertise and structure of a long-established pharmaceutical leader. The company's mission is to use its expertise, dedicated people and unique approach to innovation...

See More

Key Turning Points

2nd Resistance Point 81.31
1st Resistance Point 80.87
Last Price 80.49
1st Support Level 80.03
2nd Support Level 79.62

See More

52-Week High 107.25
Fibonacci 61.8% 95.22
Fibonacci 50% 91.51
Fibonacci 38.2% 87.80
Last Price 80.49
52-Week Low 75.77

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar